The purpose of this research study is to characterize the pharmacokinetics of intravenous
ceftazidime/avibactam in patients with Cystic Fibrosis.
Cystic fibrosis is a genetic disorder characterized by a chronic cycle of airway infection,
obstruction, and inflammation leading to progressive loss of lung function and eventual
respiratory failure. The principal pathogen is Pseudomonas aeruginosa which is present in
the airways of 70% of adult patients with CF. Of particular concern is the increasing
resistance observed to existing agents.
While ceftazidime has been the mainstay of treatment for many years, its efficacy is limited
by reduced susceptibility. Ceftazidime/avibactam offers a potential advancement in the
management of infections involving P. aeruginosa in CF due to its excellent activity,
penetration into pulmonary secretions, and reduced potential for development of resistance.
- Diagnosis of CF based on positive sweat chloride or know CF mutation
- Age > 17 years
- Able to spontaneously expectorate sputum
- Any clinically significant laboratory abnormality
- Presence of an ongoing acute pulmonary exacerbation
- Serious past allergy to a beta-lactam antibiotic